Biotechnology Investment / Closed-End Fund Management
Strategic Profile
Primary focus lies on small-to-mid-cap biotech companies headquartered in Western Europe and especially the United States market. BB Biotech targets a concentrated portfolio of 20–35 of the most promising biotech companies, with about two-thirds held in five to eight larger stocks that already have products on the market and the remaining third in stocks with promising drug candidates in advanced stages of development.
Cyborg Score Rationale
With around CHF2.4bn in assets under management, BB Biotech is the largest biotech-focused investor among its investment company peers with a 30-year legacy of identifying and backing high-impact biotech innovators. The biotech sector appears poised for significant growth with lower interest rates renewing investor interest and fueling merger and acquisition activity.
Top Insights
BB Biotech's ability to spot potential winners early, such as its pre-IPO investment in Moderna, sets it apart.
The manager's search for new opportunities is supported by three data scientists using AI and big data to synthesize data across approximately 8,000 companies developing new drugs.
Core investments as of December 31, 2024 include Argenx (13.7%), Ionis Pharmaceuticals (10.0%), and Neurocrine Biosciences (9.4%).
As of February 26, 2026, the share price was 46.35 CHF with a NAV of 50.25 CHF, representing a 7.8% discount to NAV.
Named Competitors
Biotech ETF/Mutual Fund Competitors — Broader biotech index exposure with lower fees
Specialized biotech funds — Alternative biotech investment vehicles with different fee structures
Recent Developments
(December 2024) Christian Koch appointed as new head of investment management team, replacing previous leadership
(December 2024) Portfolio showed positive fundamental progress with several holdings achieving key milestones
(March 2026) Trading at CHF 46.35 with discount-to-NAV structure providing entry opportunity at 7.8% discount
Open the full interactive BB Biotech AG report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.